BAYRY's Cardiovascular Medication Achieves Objectives in Final Phase Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Should l Buy CRMD?
Source: NASDAQ.COM
Asundexian Study Results: Bayer AG's candidate asundexian met primary efficacy and safety endpoints in the OCEANIC-STROKE study, significantly reducing the risk of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack when combined with antiplatelet therapy.
Regulatory Progress: Bayer plans to submit marketing authorization applications globally for asundexian, which has received Fast Track Designation from the FDA, marking a significant advancement in their pharmaceutical portfolio.
Pharmaceutical Growth: Bayer's pharmaceutical division is experiencing growth driven by key drugs like Nubeqa and Kerendia, compensating for declining sales of Xarelto, while the company seeks to expand the labels of these drugs to further boost sales.
Pipeline Developments: Bayer is advancing its pipeline with new drug applications, including gadoquatrane for MRI use, and has received recent approvals for elinzanetant and Hyrnuo, indicating strong momentum in their drug development efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRMD
Wall Street analysts forecast CRMD stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.910
Low
13.00
Averages
13.67
High
15.00
Current: 6.910
Low
13.00
Averages
13.67
High
15.00
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CorMedix Scheduled to Announce Q4 Earnings on March 5th
- Earnings Announcement Schedule: CorMedix (CRMD) is set to announce its Q4 2023 earnings on March 5th before market open, with consensus EPS estimates at $0.81 and revenue at $127.02 million, highlighting investor interest in the company's financial performance.
- Historical Performance Review: Over the past two years, CRMD has only beaten EPS estimates 25% of the time and revenue estimates 38% of the time, indicating uncertainty in the company's financial forecasting, which may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward and one downward revision, while revenue estimates have experienced two upward and five downward revisions, reflecting divergent market views on the company's future performance, potentially leading to stock price volatility.
- Stock Buyback Plan: CorMedix has announced a $75 million stock buyback plan aimed at enhancing shareholder value, although the recent disappointing revenue outlook for 2026 may negatively impact the stock price.
See More
CorMedix Reports Strong Q4 and Full-Year 2025 Financial Results
- Q4 Revenue Surge: CorMedix reported net revenue of $128.6 million for Q4 2025, primarily driven by continued utilization of DefenCath among outpatient dialysis customers, with sales reaching $91.2 million, indicating strong market demand and product acceptance.
- Significant Annual Performance: Total revenue for 2025 was $311.7 million, a substantial increase from 2024, and with the acquisition of Melinta, pro forma total revenue is projected to reach $401.3 million, reflecting the company's success in expanding its product portfolio.
- Improved Profitability: The company achieved a net income of $14.0 million in Q4, with adjusted EBITDA of $77.2 million, demonstrating effective cost control and operational efficiency despite a 182% year-over-year increase in operating expenses.
- Positive Future Outlook: CorMedix reiterated its guidance for 2026, expecting net revenue between $300 million and $320 million and adjusted EBITDA between $100 million and $125 million, showcasing confidence in future growth, particularly with upcoming REZZAYO clinical data releases.
See More
CorMedix to Present at Upcoming Investor Conferences
- Investor Conference Schedule: CorMedix is set to present at several investor conferences in March, including the Leerink Partners Global Healthcare Conference on March 10 and the Citizens Life Sciences Conference on March 11, aiming to enhance its visibility and credibility among investors.
- Product Commercialization Progress: The company is commercializing DefenCath® for preventing catheter-related bloodstream infections in adult patients undergoing hemodialysis, demonstrating its market potential in critical healthcare areas.
- Post-Acquisition Product Portfolio: Following its acquisition of Melinta Therapeutics LLC in August 2025, CorMedix has expanded its anti-infective product portfolio, including MINOCIN® and REZZAYO®, thereby strengthening its competitive position in the biopharmaceutical market.
- Clinical Research Updates: CorMedix is conducting clinical studies for DefenCath in Total Parenteral Nutrition and pediatric dialysis populations, with topline results for the Phase III study of REZZAYO expected in Q2 2026, potentially providing crucial data support for future growth.
See More
CorMedix's Near-Term Growth Prospects Analysis
- Clinical Data Impact: CorMedix's (CRMD) near-term growth prospects will be significantly influenced by upcoming clinical data, which will provide critical market signals for investors and potentially affect the company's stock price trajectory.
- Market Expectations: Market anticipation for CorMedix is primarily focused on its clinical trial results, where successful outcomes could enhance the company's competitiveness in the healthcare sector, thereby attracting more investor interest.
- Strategic Direction: The company is actively preparing for the forthcoming clinical data release to effectively communicate its potential market value and application prospects, further solidifying its position in the industry.
- Investor Confidence: As the clinical data approaches, investor confidence may be impacted, especially against the backdrop of heightened market focus on medical innovation, where successful clinical results could potentially drive stock price increases.
See More
CorMedix Approves $75M Share Repurchase Program
- Repurchase Program Approval: CorMedix Therapeutics' (CRMD) board has approved a share repurchase program authorizing the company to buy back up to $75 million of its common stock, reflecting confidence in its stock value.
- Repurchase Timeline: The program is authorized through December 31, 2027, with share repurchases expected to begin as early as Q1 2026, aimed at enhancing earnings per share by reducing the number of shares outstanding.
- Financial Overview: As of December 31, 2025, CorMedix had approximately $150 million in cash and cash equivalents and 79.3 million common shares outstanding, indicating the company's financial capability to execute the repurchase plan.
- Revenue Outlook Adjustment: Despite facing CMS reimbursement headwinds, CorMedix has raised its 2025 revenue guidance to $390 million to $410 million, reflecting growth potential driven by accelerated Melinta integration and DefenCath product momentum.
See More
CorMedix Approves $75 Million Share Repurchase Program
- Repurchase Program Initiation: CorMedix Therapeutics' Board has approved a share repurchase program of up to $75 million, expected to commence in Q1 2026, aimed at enhancing shareholder value while maintaining financial flexibility for business investments.
- Strong Financial Position: As of December 31, 2025, CorMedix reported approximately $150 million in cash and cash equivalents and 79.3 million shares outstanding, indicating a robust balance sheet that supports the repurchase program and reflects the company's confidence in future growth.
- Market Condition Considerations: The repurchase program will be executed flexibly based on prevailing market conditions, liquidity, and cash flow, allowing management to choose from private negotiations, block trades, or open market purchases to ensure timely execution.
- Long-term Strategic Confidence: The company expresses strong confidence in the potential of its late-stage clinical programs to deliver significant patient benefits, viewing the repurchase program not only as a return to shareholders but also as a strategic investment in future business development.
See More
CorMedix Scheduled to Announce Q4 Earnings on March 5th
- Earnings Announcement Schedule: CorMedix (CRMD) is set to announce its Q4 2023 earnings on March 5th before market open, with consensus EPS estimates at $0.81 and revenue at $127.02 million, highlighting investor interest in the company's financial performance.
- Historical Performance Review: Over the past two years, CRMD has only beaten EPS estimates 25% of the time and revenue estimates 38% of the time, indicating uncertainty in the company's financial forecasting, which may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward and one downward revision, while revenue estimates have experienced two upward and five downward revisions, reflecting divergent market views on the company's future performance, potentially leading to stock price volatility.
- Stock Buyback Plan: CorMedix has announced a $75 million stock buyback plan aimed at enhancing shareholder value, although the recent disappointing revenue outlook for 2026 may negatively impact the stock price.
See More
CorMedix Reports Strong Q4 and Full-Year 2025 Financial Results
- Q4 Revenue Surge: CorMedix reported net revenue of $128.6 million for Q4 2025, primarily driven by continued utilization of DefenCath among outpatient dialysis customers, with sales reaching $91.2 million, indicating strong market demand and product acceptance.
- Significant Annual Performance: Total revenue for 2025 was $311.7 million, a substantial increase from 2024, and with the acquisition of Melinta, pro forma total revenue is projected to reach $401.3 million, reflecting the company's success in expanding its product portfolio.
- Improved Profitability: The company achieved a net income of $14.0 million in Q4, with adjusted EBITDA of $77.2 million, demonstrating effective cost control and operational efficiency despite a 182% year-over-year increase in operating expenses.
- Positive Future Outlook: CorMedix reiterated its guidance for 2026, expecting net revenue between $300 million and $320 million and adjusted EBITDA between $100 million and $125 million, showcasing confidence in future growth, particularly with upcoming REZZAYO clinical data releases.
See More
CorMedix to Present at Upcoming Investor Conferences
- Investor Conference Schedule: CorMedix is set to present at several investor conferences in March, including the Leerink Partners Global Healthcare Conference on March 10 and the Citizens Life Sciences Conference on March 11, aiming to enhance its visibility and credibility among investors.
- Product Commercialization Progress: The company is commercializing DefenCath® for preventing catheter-related bloodstream infections in adult patients undergoing hemodialysis, demonstrating its market potential in critical healthcare areas.
- Post-Acquisition Product Portfolio: Following its acquisition of Melinta Therapeutics LLC in August 2025, CorMedix has expanded its anti-infective product portfolio, including MINOCIN® and REZZAYO®, thereby strengthening its competitive position in the biopharmaceutical market.
- Clinical Research Updates: CorMedix is conducting clinical studies for DefenCath in Total Parenteral Nutrition and pediatric dialysis populations, with topline results for the Phase III study of REZZAYO expected in Q2 2026, potentially providing crucial data support for future growth.
See More
CorMedix's Near-Term Growth Prospects Analysis
- Clinical Data Impact: CorMedix's (CRMD) near-term growth prospects will be significantly influenced by upcoming clinical data, which will provide critical market signals for investors and potentially affect the company's stock price trajectory.
- Market Expectations: Market anticipation for CorMedix is primarily focused on its clinical trial results, where successful outcomes could enhance the company's competitiveness in the healthcare sector, thereby attracting more investor interest.
- Strategic Direction: The company is actively preparing for the forthcoming clinical data release to effectively communicate its potential market value and application prospects, further solidifying its position in the industry.
- Investor Confidence: As the clinical data approaches, investor confidence may be impacted, especially against the backdrop of heightened market focus on medical innovation, where successful clinical results could potentially drive stock price increases.
See More
CorMedix Approves $75M Share Repurchase Program
- Repurchase Program Approval: CorMedix Therapeutics' (CRMD) board has approved a share repurchase program authorizing the company to buy back up to $75 million of its common stock, reflecting confidence in its stock value.
- Repurchase Timeline: The program is authorized through December 31, 2027, with share repurchases expected to begin as early as Q1 2026, aimed at enhancing earnings per share by reducing the number of shares outstanding.
- Financial Overview: As of December 31, 2025, CorMedix had approximately $150 million in cash and cash equivalents and 79.3 million common shares outstanding, indicating the company's financial capability to execute the repurchase plan.
- Revenue Outlook Adjustment: Despite facing CMS reimbursement headwinds, CorMedix has raised its 2025 revenue guidance to $390 million to $410 million, reflecting growth potential driven by accelerated Melinta integration and DefenCath product momentum.
See More
CorMedix Approves $75 Million Share Repurchase Program
- Repurchase Program Initiation: CorMedix Therapeutics' Board has approved a share repurchase program of up to $75 million, expected to commence in Q1 2026, aimed at enhancing shareholder value while maintaining financial flexibility for business investments.
- Strong Financial Position: As of December 31, 2025, CorMedix reported approximately $150 million in cash and cash equivalents and 79.3 million shares outstanding, indicating a robust balance sheet that supports the repurchase program and reflects the company's confidence in future growth.
- Market Condition Considerations: The repurchase program will be executed flexibly based on prevailing market conditions, liquidity, and cash flow, allowing management to choose from private negotiations, block trades, or open market purchases to ensure timely execution.
- Long-term Strategic Confidence: The company expresses strong confidence in the potential of its late-stage clinical programs to deliver significant patient benefits, viewing the repurchase program not only as a return to shareholders but also as a strategic investment in future business development.
See More
